Stock ALK B ALK-ABELLÓ A/S
Add to a list
To use this feature you must be a member
Log inSign up

Ratings ALK-Abelló A/S

Equities

ALK B

DK0061802139

Market Closed - Nasdaq Copenhagen
Other stock markets
 10:59:33 2024-04-29 EDT 		5-day change 1st Jan Change
130.8 DKK +0.62% Intraday chart for ALK-Abelló A/S +2.59% +29.25%
03-14 Transcript : ALK-Abelló A/S - Shareholder/Analyst Call
03-04 New entries in MarketScreener's Europe portfolio Our Logo

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.92 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ALK-ABELLÓ A/S Stock ALK-Abelló A/S
+29.25% 4.16B
B+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 567B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 234B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 196B
A+
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ALK B Stock
  4. Ratings ALK-Abelló A/S